Television star Eric Dane, beloved for his performances in “Grey’s Anatomy” and “Euphoria,” passed away this week at age 53 after battling amyotrophic lateral sclerosis, commonly known as ALS.
The progressive neurological condition took Dane’s life less than 12 months following his public announcement of the diagnosis, highlighting the aggressive nature of this devastating illness.
Data from the Centers for Disease Control and Prevention shows ALS affects a relatively small population. Researchers counted approximately 33,000 cases nationwide in 2022, with projections indicating the number could climb beyond 36,000 by the decade’s end.
The condition shows a slight preference for affecting males over females and typically emerges during middle age, most commonly striking individuals between 40 and 60 years old.
ALS targets nerve cells located in both the brain and spinal cord, resulting in progressive loss of muscle function that worsens as time passes.
The disease destroys nerve cells in both upper and lower regions of the body, causing them to malfunction and eventually die. When nerves can no longer activate specific muscles, patients gradually develop paralysis. Individuals diagnosed with ALS often experience difficulties with movement, speech, swallowing, and respiratory function.
Medical researchers have yet to identify the precise cause of this condition, though Mayo Clinic specialists note that a limited percentage of cases stem from genetic inheritance.
The alternate name “Lou Gehrig’s disease” honors the legendary New York Yankees baseball player who brought national attention to ALS. Gehrig received his diagnosis in 1939 on his 36th birthday, succumbed to the illness in 1941, and became the public face of ALS awareness for many years.
Medical professionals explain that initial symptoms often appear mild and easy to overlook. The condition frequently starts with muscle spasms and weakness affecting a single arm or leg.
As the disease advances, muscles lose their ability to function properly, according to specialists at University of California San Francisco Health. Patients may experience declining strength and coordination in their limbs, weakness in feet and ankles, and cramping or spasms in muscles of the arms, shoulders, and tongue. Difficulty swallowing and speaking often develop alongside persistent exhaustion.
UCSF medical experts emphasize that cognitive abilities and the five senses – sight, hearing, smell, taste, and touch – typically remain unaffected by the disease.
In advanced stages, muscles responsible for breathing may become paralyzed. Patients often lose the ability to swallow properly, leading to aspiration of food or saliva. Respiratory failure represents the leading cause of death among ALS patients.
Diagnosing ALS presents significant challenges since no single test or procedure can definitively confirm the condition. Medical professionals typically conduct comprehensive physical examinations, laboratory testing, and brain and spinal cord imaging.
Physicians look for specific indicators that may suggest ALS, including abnormal toe reflexes, decreased fine motor skills, painful muscle cramping, involuntary muscle twitching, and spasticity characterized by stiff, jerky movements.
While no cure exists for ALS, the medication riluzole has received approval for treatment purposes. Mayo Clinic research indicates this drug may prolong survival during early disease stages or delay the need for mechanical breathing assistance.
Relyvrio, another treatment option that generated significant controversy, was withdrawn from American markets by Amylyx Pharmaceuticals in 2024. The ALS Association, which gained prominence through the viral 2014 “ice bucket challenge” fundraising campaign, had partially funded the drug’s development.
Additional medications are sometimes prescribed to help manage specific symptoms as they arise.
As ALS progresses, choking becomes increasingly frequent, often necessitating feeding tube placement. Patients may require mobility aids like braces and wheelchairs, as well as communication devices including speech synthesizers and computer-based systems.
Following symptom onset, medical experts indicate survival times range from two years to a full decade. The majority of patients live between two and five years after symptoms first appear, while approximately 20 percent survive beyond the five-year mark following diagnosis.
